Ribaxa+ 150mg Tablet

About Ribaxa+ 150mg Tablet

Ribaxa 150mg Tablet contains Olaparib, a targeted anticancer medication that belongs to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is used in the treatment of certain cancers, including prostate cancer and metastatic pancreatic cancer, by blocking PARP enzymes that cancer cells rely on to repair damaged DNA, ultimately slowing cancer growth and promoting cancer cell death. Depending on the patient's condition and treatment goals, Ribaxa 150mg Tablet may be prescribed alone or in combination with other anticancer therapies. Before starting treatment, patients should inform their healthcare provider about any history of liver, lung, heart, or kidney disorders, as these conditions may require additional monitoring during therapy. Regular blood tests may be recommended to assess blood cell counts and overall treatment safety. Ribaxa 150mg Tablet is not recommended during pregnancy or breastfeeding because it may cause harm to an unborn baby or nursing infant. Women of childbearing potential should undergo a pregnancy test before starting treatment and use effective contraception throughout therapy as advised by their doctor. Male patients should avoid donating sperm during treatment and for at least three months after the final dose. Regular medical follow-up and adherence to prescribed treatment are essential to ensure the safe and effective use of Ribaxa 150mg Tablet in managing advanced cancers and improving treatment outcomes.